Healthpeak Properties stock (US42226K1051): Baird, Citi and Jefferies raise price targets

Healthpeak Properties, a leading healthcare REIT, has attracted fresh attention from Wall Street analysts. Baird recently adjusted its price target upward to $21 from $19 while maintaining an Outperform rating, according to Marketscreener as of recent update. Citi raised its target to $20 from $17.50 with a Neutral rating on October 5, 2023, per TipRanks. Jefferies also lifted its target to $19 from $16, keeping a Hold rating.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Healthpeak Properties: core business model

Healthpeak Properties owns, operates and develops real estate focused on healthcare delivery and discovery across the United States. The company functions as a fully integrated REIT with segments including Lab, Outpatient Medical and Continuing Care Retirement Communities (CCRC), according to its profile on Marketscreener. It acquires, leases and manages properties tailored to healthcare needs, benefiting from long-term leases with stable tenants like hospitals and labs.

This model positions Healthpeak Properties to capitalize on the growing demand for specialized healthcare infrastructure in the US, where aging demographics drive expansion in medical facilities and research spaces.

Main revenue and product drivers for Healthpeak Properties

Revenue primarily stems from rental income across its Lab segment, which supports biotech and life sciences research, Outpatient Medical properties serving clinics and physician offices, and CCRC for senior living. These diversified assets provide resilience, with lab spaces seeing high demand from innovation hubs. The stock last closed at 19.78 USD, near the average analyst target of 19.83 USD as noted by FactSet data on Marketscreener.

Healthpeak Properties' exposure to high-growth areas like life sciences labs makes it relevant for US investors tracking healthcare real estate trends amid biotech booms.

Industry trends and competitive position

The US healthcare REIT sector benefits from steady demand due to an aging population and advances in medical research. Healthpeak Properties holds a strong position with its focus on lab and outpatient assets, differentiating it from peers more reliant on traditional hospitals. Consensus ratings lean overweight with a mean target around 19.88 USD per FactSet.

Why Healthpeak Properties matters for US investors

As an S&P 500 constituent listed on NYSE under DOC, Healthpeak Properties offers US investors direct exposure to healthcare real estate, a defensive sector with inflation-hedging potential via rents. Its properties serve key US markets, aligning with domestic economic trends like biotech funding and senior care needs.

Conclusion

Healthpeak Properties continues to draw analyst interest with recent price target increases from Baird, Citi and Jefferies, reflecting confidence in its healthcare real estate portfolio. The company's segments in labs, outpatient medical and CCRC provide diversified revenue amid US sector growth. Investors monitor NYSE:DOC for updates on occupancy and development pipelines.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.